CFDE Data Portal | Search ULK4P1

	Label	Description
	ULK4P1 associations Collection (Entity type)	Associations for ULK4P1_associations
	ULK4P1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	ULK4P1 Gene (Entity type)	ENSG00000291023 - ULK4 pseudogene 1
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 3 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE218060 decitabine T cell 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151083 enzalutamide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 0 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS

ULK4P1 associations

Associations for ULK4P1_associations

ULK4P1 associations.tsv

A file from IDG as part of the Harmonizome project

ULK4P1

ENSG00000291023 - ULK4 pseudogene 1

GSE216043 cisplatin 7 v 0 human dn

A Gene Set from LINCS

GSE128076 doxycycline HEK293 1 v 3 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 3 v 6 human dn

A Gene Set from LINCS

GSE218060 decitabine T cell 1 v 4 human up

A Gene Set from LINCS

GSE216043 cisplatin 11 v 1 human dn

A Gene Set from LINCS

GSE151083 enzalutamide 0 v 1 human up

A Gene Set from LINCS

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 0 v 4 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.